Physician profile
Ju Y Kim
NPI 1710764550
$1,622.09
in general payments reported to CMS, 2019-2025
15 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $546 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $353.63 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.01 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $207.34 | 2024-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $155.45 | 2024-2025 | Verquvo |
| Amgen INC. | $135.23 | 2024-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $95.64 | 2025 | |
| Bridgebio Pharma, INC. | $88.07 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $67.95 | 2025 | |
| Scpharmaceuticals INC. | $36.61 | 2025 | |
| Pfizer INC. | $31.66 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $28.75 | 2024 | Evkeeza |
| Abiomed | $23.17 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.51 | 2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $17.21 | 2025 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $16.86 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ju Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.